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[571 ABSTRACT 
The present invention is an apparatus and a method of 
detecting a chemical released by perspiration, typically 
through sweat and broadcasting the detection to a receiver. 
The chemical may be a drug of abuse. The device which is 
attached to the skin of a subject contains labeled antibodies 
or label containing microspheres attached to antibodies. The 
labeled antibodies are bound to solid phase drug via antigen- 
antibody interaction. These labeled antibodies are displaced 
from the solid phase support to which they are bound by free 
drug molecules in the perspiration. These labeled antibodies 
then migrate through a spacer layer and are trapped by a 
layer containing a suitable selective binding material. The 
label is illuminated or excited by a light source and detected 
by a photodetector. The signal can be recorded, or transmit- 
ted to a remote radio monitor. 
20 Claims, 6 Drawing Sheets 
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REAL-TIME BIOCHEMICAL ASSAY 
TELEMETERING SYSTEM 
The application is a continuation to refer to the filing date 
of prior application Ser. No. 081694,923, filed Aug. 8, 1996, 
now abandoned. The prior application was abandoned on 
Dec. 24, 1996, after the filing of the present application on 
Dec. 19, 1996. 
ORIGIN OF THE INVENTION 
The invention described herein was made in the perfor- 
mance of work under a NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 USC 202) in which the 
Contractor has elected to retain title. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to a process and apparatus 
for the detection of drugs and other biochemicals present in 
a human or other mammalian system and the reporting of the 
detection telemetrically to a receiver. The present invention 
is particularly suited for monitoring parolees and others for 
drug use, monitoring medical conditions of patients, and 
remote monitoring of biochemical parameters of subjects in 
space. 
2. Background Art 
Agencies of the criminal justice system utilize a variety of 
techniques for monitoring convicted persons either in insti- 
tutions or in various less secure settings within the commu- 
nity. One successful method for monitoring convicts in a 
non-institutionalized setting employs a telemetry bracelet 
for locating persons at home or at work locations. In these 
systems, a device attached to the paroled convict signals a 
receiver attached to a telephone system to report the con- 
vict’s whereabouts relative to the receiver. Parole conditions 
may also include prohibitions on the use of controlled 
substances, especially in cases of convictions involving drug 
use. Additionally, convicts who are incarcerated are also 
supposed to be prohibited from using controlled substances 
during incarceration. Due to manpower and budgetary 
constraints, only a small fraction of the existing parolees can 
be tested for drug use at any one time. Therefore, for these 
types of situations, it would be desirable for telemetry 
devices, similar to those presently being used for the 
parolees, such as telemetry bracelets, to actively monitor for 
the presence of controlled bioactive substances in a non- 
invasive and continuous way. 
In a medical setting, hospitals and home care medical care 
operations require that various biochemical parameters be 
carefully monitored. For example, diabetics must control 
their blood sugar levels and blood insulin levels carefully. 
Patients with infections must maintain a minimum antibiotic 
level in their system. Patients with various chronic ailments 
are required to take regular doses of medication, such as 
epileptic patients on anti-epileptic drugs. The continuous 
and non-invasive monitoring of such patients is also desir- 
able. The medical community may also find it desirable to 
monitor the levels of prescribed medications and detect 
overdoses of such medications in order to come to the aid of 
such patients as soon as the problem is detected. 
Such sensor/telemetry technology has applications to 
NASA activities as well where biological substance detec- 
tion could be employed in process control for life support 
systems and in the remote manipulation and analysis of 
space borne biological and medical experiments. 
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Liotta, U.S. Pat. No. 4,837,145 discloses a device for 
determining the presence of an antigen which comprises a 
trapping zone, which contains material capable of capturing 
free flowing enzyme linked antibodies, but not antibodies 
bound to a transport particle which flows freely through the 
trapping zone into the substrate zone, and a substrate zone 
which contains material capable of reacting with enzyme- 
linked antibodies to produce a reaction which indicates the 
presence of antibodies. A method of determining the pres- 
ence of an antigen is also disclosed wherein a sample is 
mixed with two classes of antibodies which are specific for 
the antigen being tested for, but which react with different 
antigen domains, wherein the mixture consists of class one 
antibodies bound to a transport particle which flows freely 
through the trapping zone and class two enzyme-linked 
antibodies which are incapable, unless bound to the trans- 
port particles, of flowing freely through the trapping zone. In 
the presence of the antigen being tested for, both classes of 
antibodies bind to the antigen and flow through the trapping 
zone into the substrate zone, wherein a reaction takes place 
to indicate the presence of the antigen. 
Liotta, U.S. Pat. No. 4,446,232 discloses a device for 
determining the presence of antigens which comprises a first 
zone containing antigens and enzyme-linked antibodies 
which are capable of immunologically reacting with said 
antigens, said antibodies being positioned in said first zone 
such that they will be removed from said first zone when 
reacted with antigens passing through said first zone but not 
removed from said first zone in the absence of such antigens, 
and a second zone containing material capable of reacting 
with said enzyme-linked antibodies to produce a color 
forming reaction which indicates the presence of said anti- 
bodies. Hiratsuka et al., U.S. Pat. No. 4,337,065 also dis- 
closes a multilayer device for determining antigens similar 
to U.S. Pat. No. 4,446,232 except for the detection being by 
development of a silver halide film. 
In 1991, Dr. David Kidwell reported the development of 
a simple to use device for field testing urine and saliva for 
the presence of drugs of abuse, specifically, cocaine. The 
device is called a microassay on a card, or MAC. It consists 
of a small flat plastic card (2 inchesx2 inchesx0.2 inches) in 
which all of the reagents required for the cocaine assay are 
provided. To run the test, a sample of saliva or urine, 50 pl, 
is placed in a well; the urine or saliva is drawn through a 
semipermeable membrane into the MAC via capillary 
action. If the drug is present, a calorimetric reaction occurs 
and becomes visible within 5 minutes on the card. The MAC 
test is more fully described in U.S. Pat. Nos. 5,200,321 and 
5,369,007, incorporated herein by reference. As described in 
U.S. Pat. No. 5,200,321, the microassay card includes an 
upper layer containing wells for receiving a liquid sample, 
a second layer of the card, beneath the first layer, which 
includes a supporting surface bound to a reactive species, 
and a third layer which includes an absorbent support 
impregnated with an indicator. Typically, the indicator is a 
substrate for an enzyme, such as a reduced dye precursor and 
a source of hydrogen peroxide necessary for the action of the 
enzyme upon the substrate to cause a spectral change in the 
absorbent layer. The microassay card is particularly useful 
for drug testing. 
The MAC operates by virtue of an antibody-antigen 
interaction. Disposed within the MAC is an absorbent paper 
layer to which a drug sample (antigen) is covalently bound. 
Enzyme labeled anti-drug antibodies are immobilized on 
this layer by an antigen-antibody interaction. If the drug to 
be detected is present in the saliva or will displace the bound 
anti-drug antibody, which then can travel through the system 
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and reach a layer of substrate. The enzyme attached to the 
antibody causes the substrate to change color, giving a visual 
signal for presence of the drug. 
It would thus be desirable to provide a system which 
system with a wide range of potential applications. The 
stability of the biological reporter m0kCUkS such as 
antibodies, enzymes, and the like. 
TABLE 1-continued 
MEASURED DRUG CONCENTRATIONS IN PERSPIRATION* 
integrates the microassay system with a sensoritelemetry 5 DRUG CONCENTRATION @g/ml) RANGE @g/ml) 
I. Ishiyama, et al: “The Significance of Drug Analysis of Sweat in Respect to 
**G. I. Henderson, M. R. Harkey and R. Jones, “Final Report-Hair Analysis 
for Drugs of Abuse”, National Institute of Justice, Grant #90-NIJ-CX-0012, 
are limited then Only by the and Rapid Screening for Drug Abuse”, Z, Techtsmed, 82 (1979) p 251-256, 
10 Sept, 1993. 
SUMMARY OF THE INVENTION The drug badge of the present invention consists of a 
wristwatch or adhesive bandage (“Band Aid@”)-like 
device that is attached to the skin. Sweat from the skin 
passes into the drug detection patch through a semiperme- 
The present invention comprises, in its preferred 
embodiment, a method and apparatus for detecting drugs or 
Other 
(perspiration being defined as both 
detection 
Or from the perspiration 15 able membrane. Only small molecules (drug, water, salts, 
etc,) will pass through the membrane; large molecules and 
without this membrane, its presence assures sterility and 
and sebaceous 
secretions) of individuals and reporting the results of the 
comprises a series of polymer layers containing antibodies 
which specifically bind substances of interest and which are 2o 
induced to migrate from sites of immobilization to sites of 
antibody from its immobilization site by competitively bind- 
bacteria will be excluded, While the device will work 
provides flow rate control through the device, 
The apparatus of the present invention contains small 
fluorescent or enzyme labeled antibodies which are bound to 
from the solid phase support to which they are bound by any 
The apparatus Of the present invention 
detection by which have the labeled solid phase drug. These labeled antibodies will be displaced 
ing to it. These polymer layers can be packaged in laminate free drug molecules in the sweat. These labeled antibodies 
form Or can exist in separate packages which are then fluid 25 can then migrate through a moist layer (such as filter paper) 
flow connected by tubing Or Other conduit. A to the distal side of the badge (driven by transpiration) and 
molecule coupled reaction linked to the migrating antibodies be trapped by a polymer layer containing anti-antibodies, or 
then alters the light emission of the most distal polymer layer other suitable trapping material, The three layers of: solid 
which interfaces to the photodiode-based illumination/ phase label, spacer, and trap, form a ~ i ~ ~ h ~ ~ i ~ ~ l  Diode- 
detection electronics and logic. The substance detection 3o Capacitor (BDC) which is discussed in detail below, The 
subsystem if the drug or other substance were present. signal into a small volume, and allows the signal to be 
It is an object of the present invention to provide a integrated over time. The fluorescent or calorimetric signal 
chemical detection and signaling system which detects the is excited by a light source and detected by a photodetector. 
transpiration of substance(s) of abuse using a driven bio- 35 Alternatively, the change in reflectance due to the presence 
chemical detector specific for the substance. of the calorimetric material is sensed by a photodetector. The 
It is a related object of the present invention to provide signal can be recorded or transmitted to a remote radio 
such a system having performance characteristics applicable monitor. 
to the continuous (real-time) monitoring of drugs in sweat, The device may also incorporate electronics for the mea- 
40 surement of skin temperature, skin conductivity and/or pulse It is another object of the present invention to utilize an rate. Although these variables change with exercise and electronic interface capable of translating that signal into day-to-day activities, the rate of change and the duration of electronic form suitable for transmission to a remote moni- change can indicate the presence of stimulants or depres- toring station. sants in the body. Such a combination sensor monitoring 
45 may reduce the false positive rate of each individual sensor. 
Alternatively, only a single sensor may be employed under 
certain applications. For example, if it is desirable to moni- 
tor an individual remotely and only determine stimulant use 
(by drugs such as cocaine or amphetamines), pulse rate 
SO monitoring may be satisfactory. If the pulse rate did not 
increase for a given period, then that individual need not be 
summoned for more extensive testing. If the pulse rate 
increased, then further testing could be used to determine if 
the pulse rate increase was due to drugs or other causes. 
ss Simple sensors can reduce the need for testing with the cost 
DRUG trade-off being the cost of the sensor array versus the cost of 
Methamphetamine 1.4 0.88-1.42 summoning the individual and performing more extensive 
Morphine 1.5 0.31-2.7 testing. These sensors can also aid in determining removal of 
THC 0.32 0.034-1 .O the device because the body temperature will drop or the 
Cocaine 9 1-50 ,ug/,ul** 
Methadone 0.48 0.31-0.86 The system for monitoring the color change signal con- 
Cotinine (nicotine 0.51 0.10-0.93 sists of a light source illuminating the appropriate polymer 
metabolite) layers and a series of photodetectors with associated elec- 
*s, Balabanova, and E, Schneider: “Nachweis non Drogen im Schweiss,,, 65 tronics to detect changes. The detector and light modulation 
Beitrage Zur Gerichtlichen Medizin, 48 (1990) p. 4549. circuitry provides pulse modulation to reduce effects of 
ambient light false triggers. Other detection precautions 
initiates a sequence to the BDC prevents the label from backflowing, concentrates the 
Drug Badge Design 
Biochemical System 
The present invention utilizes the following information 
based upon the fact that most drugs are eliminated from the 
body in significant amounts by the sweat glands (see Table 
1). 
TABLE 1 
MEASURED DRUG CONCENTRHIONS IN PERSPIRATION* 
CONCENTRHION RANGE @dml) 
60 pulse rate will be lost. Benzodiazepine 0.19 0.14-0.33 
Barbiturate 70 66-74 Electronic Interface 
5,891,649 
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employed in the signal detection system will consist of 
comparing several cells for a change prior to triggering an 
alarm. For a confidence and calibration test, some cells that 
do not change are monitored and compared continuously. 
After a change is detected, a modulation signal turns on a s 
small transmitter. The signal from this transmitter is detected 
at a remote monitoring site, T~ accommodate the monitoring 
and held in place by antibody bound to the solid phase; it 
would be the labeled drug that would then be released by 
free drug (in a sample) and would migrate to the trap layer 
to be detected. The trap in that case would consist of a 
component to bind to the label Or to the label carrier, the 
carrier being either the drug itself Or another component 
such as microspheres. The microspheres can contain other 
of several people, the signal can be provided with a special 
code for each user, The device may also be supplied with a 
groups besides the label as proteins, ion exchange 
groups and sugars that can bind to the trap component. In the 
descriptions to follow, the focus will be on the drug as bound means for signaling the removal of the device so that, for i o  to the solid phase and the antibody containing the label: it is 
detection of chemicals in the sweat. Long distance trans- even if not explicitly stated, It will also be understood that 
mission is very power intensive. The detector and transmit- while the present invention is described in terms of drug 
ter and remote receiver may have an intermediate device to detection, any chemical which is bindable to an antibody or 
Save Power. The wrist size device may have a low Power 15 other bioconjugate may be detected in accordance with the 
transmitter which transmits to a receiver close by or on the present invention, 
individual. This intermediate transmitter may contain a Component 81 is a spacer separating the Displacement 80 
storage device to Save Sensor readings and record the and the Trap 82 components. The Spacer 81 optically and 
positional location of the individual before interrogation by biochemically isolates these two components (80 & 82). The 
the remote site. 20 Spacer can be made of polymer material such as common 
a drug cannot remove the device to avoid always implied that the is just as acceptable 
BRIEF DESCRIPTION OF THE DRAWINGS 
fiiter paper for use in a laminate form of the BDC or can be 
tubing made of polyethylene or other common plastic, or - .  . 
metaifor use in a pumped flow-through form ofthe BDC. FIG. 1 is a schematic block diagram of the relationship of The opticalbiochemical isolation function of the spacer 81 the basic components of the present invention. 
2s can be incorporated into the displacement layer through 
diagram Of the proper choice of displacement layer materials and chemical 
arrangement and operation of the transpiration driven lami- procedures, F~~ example, a sufficiently thick filter paper 
nate form of the present invention. derivatized on one side with covalently bound drug and 
FIG. 3 is a schematic view of the operation and structure antigenically bound labeled antibody could effectively act as 
of a “saturation mode” form of the badge of the present 30 the spacer layer 81 when oriented with its underivatized side 
invention and the detection system for the target drug. toward the trap layer 82: opticallybiochemically isolating 
the antigenically bound labeled antibody from the trap 82 
operation of the badge of the present invention for the target and detector layers 84. Component 82 is the label Trap. The 
drug including the detection and telemetry systems. trap restrains movement of labeled antibody through the 
FIG, 5 is a schematic of an operational example of the 35 BDC enabling increased fluorescent signal to be presented to 
present invention in Pumped Flow-Though mode. the detector. The trap is made up of derivatized polymer such 
as filter paper or polymer beads containing chemical or FIG. 6 shows results from the operation of the Pumped biological active groups that can bind the labeled antibody. 
40 protein-(;, lectin (such as Concanavalin-A), and ion 
exchange groups. Additionally, while the binding molecule 
for binding the drug in the presently preferred embodiment 
The present invention includes a “BDC” or “Biochemical is an antibody, it will be recognized that other binding 
Diode-CaPacitor”, the Seven components of which are molecules can be utilized without departing from the spirit 
depicted in FIG. 1. The name ‘‘BDc’ is derived by analogy 45 and scope of the present invention. The method of chemi- 
to an electronic circuit containing a diode connected to a cally coupling these b io~ogica~~y active groups to polymers 
capacitor which Permits one-way current flow and thus the is commonly known to those well versed in the art. The Trap 
storage of charge in the capacitor. Another term for such an 81 can also physically restrain the labeled antibodies by 
electronic circuit (and by analogy the BDC) is “integrator”. molecular sieving action as with dialysis tubing or other 
The BDC is a fluid flow control device which allows signal 50 small pore filter material. The trap 82 can also perform the 
molecules to flow from the sample part of the device to be functions of the spacer layer 81 with proper choice of 
traPPed/concentrated at the detector Part of the device: materials and chemical procedures. For example, a trap layer 
allowing the signal to be integrated over time. consisting of sufficiently thick, dark filter paper derivatized 
The following is an explanation of the seven components on one side with anti-antibodies could effectively act as a 
of the schematicblock diagram which is FIG. 1. The three 5s spacer layer when oriented with its underivatized side 
central components are the Displacement 80, the Spacer 81, toward the displacement layer 80. The Detector 84 detects 
and the Trap 82 components. These components can be the optical signal trapped in 82. The detector consists of a 
connected directly together to allow fluid flow, or can be light source and optical detector pair with associated optical 
connected by a fluid channel of some sort such as tubing. filters. The filters can be narrow band interference filters or 
These connections are generalized by the line labeled 86 in 60 can be monochromators made up of diffraction gratings or 
FIG. 1. The displacement component 80 contains labeled prisms or be plastic colored filters such as sold by Kodak 
anti-drug antibodies which are held in place by solid phase under the Wratten trademark. 
bound drug (antigen). The label can be fluorescent, Examples of light sources are: LEDs (light emitting 
Phosphorescent, enzyme, dyed-microsphere or other anti- diode), laser diodes, and light sources commonly used in 
body label commonly used by those well versed in the art. 65 spectrofluorimeters and spectrophotometers (xenon lamps, 
The functional roles of antibody-antigen can also be carbon arcs, tungsten bulbs). Examples of detectors are: 
reversed if desired; that is, the drug molecule can be labeled photodiodes, phototransistors, and photomultiplier tubes. 
2a-b is a schematic 
FIGS. 4a-d illustrate an overall schematic view of the 
F1ow-Through mode BDC Of the shown in 5’ Examples of such groups are: anti-antibodies, protein-A, 
DETAILED DESCRIPTION OF THE 
INVENTION 
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The Pump 83 or Alternate Pump 83a component forces enzymes capable of providing optically readable signals 
fluid through the BDC system. This allows label released when provided with a substrate, colloidal particles, polysty- 
from the Displacement 80 component to travel through the rene latexes and other markers known in the art. In the 
Spacer 81 to the Trap 82 where it is viewed and detected by presently preferred embodiment, the labeled antibodies are 
the Detector 84. s drug specific mouse monoclonal antibodies (of Fab frag- 
components  that  make UP the BDC.  In actual  fluorescent dye. Mouse monoclonal anti-drug antibodies, or 
implementation, the BDC can be described as existing in polyclonal anti-drug antibodies are available from a number 
three manifestations or “modes”. These modes depend upon of including sigma, T~~~~ Red dye conjugation 
Flow-Through” mode and consists of an active pump-the 
dternate pump ~3~ component in FIG, lPand an active The next element of the present invention is an optical 
injector-the ~~j~~~~~ 85 component-~or applying sample filter 23 which functions to reduce background and increase 
FIG. 1 gives the overall relationship of the different merits of these antibodies), conjugated with Texas Red 
the pumping system chosen. The first One is the ‘‘hmped 10 systems are available from Molecular Probes, Inc, 
to the system. An example of this mode is shown in FIG. 5 
and will be described in more detail later. The second mode 
sensitivity by band Of 
light (centered near 615 nanometers) to reach the photode- 
Only a narrow 
is the “Saturation” mode where the pump 83 component 15 tector. An example of such a filter is an interference filter 
consists of SAP (superabsorbent polymer), The SAP will made by vacuum deposition of dielectric layers-of glass as 
draw fluid through the system until its maximum fluid is commercially available from Edmund Scientific Co. 
capacity is reached. This mode is shown in FIG. 3 and its Aphoto-detector 24 is supplied to detect an optical signal 
accompanying text. The third mode is the ‘‘Transpiration” and transduce it into an electrical signal for further process- 
mode which also uses S A P  for a Pump 83 component, but ” ing. For use with a Texas Red dye, the photodetector detects 
in this case evaporation from the S A P  surface allows con- a light emission wavelength of 615 nanometers. It will be 
tinual flow through of fluid. The S A P  is an optional corn- obvious to persons or ordinary skill in the art that the 
ponent that may be replaced by more conventional &or- photodetector can be selected for sensitivity to the appro- 
bents such as filter paper. This is discussed in more detail in priate emission of the fluorescent or calorimetric signal to be 
the text associated with FIG. 2. ’’ provided by the system selected for the present invention, 
In both the second and third modes, the Injector 85 can be many of which are known in the art. In the Preferred 
considered to be the BDC to a sampled surface interface, embodiment of the present invention, for use with the Texas 
FIG, 2 depicts in schematic form the present invention as Red dye, a Mercury-Cadmium Telluride photodiode obtain- 
a perspiration monitoring badge using the “Transpiration 3o able from New 
Mode” BDC. Starting from the proximal surface of the The next element of the present invention is an LED 
present invention, the first element is a semipermeable (Light Emitting Diode) 28 which functions to excite the 
membrane 12 which excludes high molecular weight corn- Texas Red Dye. Included with the LED is a filter 28a similar 
Photoconductor may be used. 
ponents of sweat (including particles and aggregates), main- to filter 23 except that it has a passband centered on the 
tains sterility, and allows flow of small molecules and water 35 Texas Red excitation wavelength of 595 nanometers. The 
into the device. Semipermeable membranes are known in LED of the present invention is a yellow light emitting 
the art, and presently, the preferred embodiment is made of silicon diode which can be obtained from various electronics 
polycarbonate and can be obtained from commercial sources companies including Motorola, Texas Instruments and the 
such as Nucleopore (Pleasanton, Calif.) or Poretics c o .  like. It will be obvious to persons of skill in the art that other 
(Livermore, Calif.) 4o LEDs or excitation means can be utilized without departing 
Bound to a solid polymer support 14 is a layer or area of from the spirit of the present invention, and further, that the 
covalently bound drug 16 which holds labeled antibodies in particular LED selected can be chosen to coincide with the 
place. This area is made from various drugs or drug analogs dye Or other signal means used without undue exPerimen- 
which are bound to a chemically derivatized paper or other tation. 
polymer. An example of such covalently bound drug is 45 The next element of the present invention is the super- 
amphetamine bound to carbonyldiimidazole activated paper. absorbent polymer (SAP)  13a layer. In the presently pre- 
Commercial sources of drugs and drug analogs, activation ferred embodiment, the polymer is made from derivatives of 
chemicals, and activatable papers for the covalent bonding, polyacrylic acid. This composition can be obtained from a 
are available from various companies, including Sigma number of commercial sources. The SAP 13a layer and the 
Chemical Co. and Pierce. 14, 16 & 18 comprise the Dis- so semipermeable membrane 29 form the transpiration pump 
placement component of the BDC. (See also U.S. Pat. No. that drives fluid through the system. Evaporation through the 
5,196,302, incorporated herein by reference). Free drug 17 semipermeable membrane prevents irreversible SAP satu- 
from sweat is also depicted. The next layer is the spacer 14a ration. 
which optically and biochemically separates the displace- FIG, 3 is an illustration of the application of the present 
component, from the trap component and can be ss invention as a perspiration monitoring badge for drugs of 
composed of similar base material as support 14. abuse using the “Saturation Mode” BDC, and is shown in 
In the next layer 27 are bound anti-antibodies 18a which schematic format. More particularly, FIG. 3 shows the 
capture and hold displaced labeled antibodies 20 which have invented badge, an enlargement of a portion of the badge and 
formerly free drug bound to it. These anti-antibodies may be, an enlargement of a portion of the enlargement, as explained 
for example, rabbit or goat anti-mouse IgG, as is well known 60 in more detail below. The badge 30 has a generally rectan- 
in the art. Commercial chemical supply companies such as gular cross-section. On the surface of the badge 30 is an 
Sigma Chemical Co. and VWR are sources of the anti- adhesive layer 32 which attaches the badge to the skin. 
antibodies. Layer 27 can be made of polymer similar to layer While an adhesive attachment is not essential, and other 
14. Elements 27 8~ 18a constitute the Trap component of the attachment means such as a mechanical attachment can be 
BDC. 65 used, and adhesive attachment provides a secure attachment 
The labeled antibodies 22 are drug specific antibodies that system. The first layer is a semipermeable membrane 33 
carry a fluorescent dye marker or other marker, such as which acts as a protectant and a vapor barrier to permit only 
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small molecular weight molecules into the badge system, 
including the sweat and any drug to be detected, and to 
entrap the transpired sweat into the badge once it permeates 
the membrane. Layer 33 is optional. The next layer of the 
badge is an absorbent paper 34 containing immobilized drug 
and bound spheres, described in more detail below. Element 
38 is an enlarged view of a portion of the absorbent paper 34 
showing that the paper has distributed throughout it 
covalently bound drug and immobilized antibody labeled 
microspheres. 
As mentioned above, FIG. 3 also has an enlargement of a 
portion of the absorbent paper with the covalently bound 
drug and fluorescent microsphere labeled antibody. In the 
presently preferred embodiment, the labeled antibodies are 
drug specific mouse monoclonal antibodies conjugated to 
polystyrene latexes which are fluorescently labeled. The 
polystyrene latexes termed TransFluoSpheres available from 
Molecular Probes, Inc. are preferred with the 6331720 ver- 
sion most preferred. Specifically, the paper 38 has the drug 
39 covalently bound to it through linkage 37. The fluores- 
cent labeled antibody 40 is bound through standard 
antibody-antigen binding to the drug. As explained 
previously, when drug molecules are present they compete 
with the immobilized drug for binding sites on the labeled 
antibody, causing the antibody to be released from the 
immobilized drug, and migrate through the badge system as 
described in more detail below. 
Returning to the schematic of the badge, the next layer is 
a layer of blotter paper and screen 42 which forms the 
Spacer component (see 81 of FIG. 1) of the BDC. The next 
layer is the superabsorbent polymer 44 which has been 
previously described. The SAP may be replaced by filter 
paper which may also act as an absorbent when sweating is 
light. In this case the SAP has the additional function of 
acting as the Trap component (82 FIG. 1) of the BDC, since 
the microspheres become immobilized in the sieve-like 
polymer matrix. The next layer is a tissue layer 46, and 
finally a transparent plastic layer 49 which acts as a pro- 
tectant and vapor barrier while allowing the optical signal to 
pass through to the detector (not shown). 
Layer 49 acts as a vapor barrier from the outside- 
allowing sweat to evaporate through the device but no water 
from the exterior to enter. Polycarbonate membranes with 
pore sizes of 0.02-0.2 microns are satisfactory with 0.05 
microns being preferred. 
FIG. 4 is an overall view of the Drug Badge system of the 
present invention. As shown in FIG. 4 4  the apparatus 50 is 
attached to the skin of a user by adhesive pads 52. Perspi- 
ration shown by arrows 54 containing drugs (diamond 
shapes) 56 moves in the direction ofArrow 57 which depicts 
the direction of fluid flow, as a result of the superabsorbent 
material contained in the badge, and the evaporation of the 
perspiration. 
In FIG. 4b, the free drug 56 from the perspiration moves 
through the paper 58 where the covalently bound drug 59 is 
attached. The covalently bound drug 59 has antibodies 60 
attached to it by standard antibody-antigen interaction. By 
virtue of competition for the antibody binding sites, the free 
drug from the perspiration 56 binds to the antibody to form 
a complex 62 of displaced labeled antibody and non-solid 
phase bound drug. This complex 62 then migrates to the 
bound anti-antibodies 64 which are then viewed by the 
photodetector 66. The filter and light sources are not shown 
in this drawing for simplicity. 
FIG. 4c shows the entire assembled badge including the 
detection system 70 and the retention strap 72. An antenna 
for transmitting a signal can be built into the retention strap 
72. The electronic transmission system is well known in the 
art and is presently in use in home detention systems and 
other similar devices, and therefore, is not separately 
s described herein. FIG. 4d shows a reception unit 74 with an 
antenna 75 and a system for detecting receipt of a signal 76 
indicating the presence of a chemical being detected and 
transmitting a signal to a remote receiver to forward that 
information. 
It should be noted that the badge in FIG. 4c could be made 
up of cells, each one with a separate detector, or a detector 
that “poles” each cell. A multiple cell system is one way to 
detect more than one drug at a time (multiple labels is 
another). 
When photodetector 66 detects the emission of light of a 
predetermined wavelength it sends a signal to a receiver 
which then, through any of a variety of means, such as 
telephone or electronic radio signal transmission, will signal 
a receiver that the drug, or other composition has been 
It will be appreciated by persons of skill in the art that 
other designs and processes to implement the present inven- 
tion can be used without departing from the spirit and scope 
10 
2o detected. 
25 of the present invention. 
EXAMPLE 
The following is an example of use of the present inven- 
tion in Pumped Flow-Through mode. See FIG. 5 .  This 
30 example uses Biotin as a drug analog. 
Displacement Layer 90a 
Cellulose, was chosen as the starting material for the 
displacement layer. Laboratory grade filter paper is a high 
purity material with uniform, well-characterized wetting 
properties that is robust and easy to handle. In addition the 
synthetic chemistry of its derivatization has been well estab- 
lished. Biotin derivatized filter paper was used in this 
example. 
3s 
4o Trap Layer 92a 
Beaded agarose was chosen as the packing material in the 
trap cell. Agarose is a common polysaccharide matrix used 
in low pressure liquid chromatography and there are a 
wealth of reagents available for covalently coupling ligands 
45 to it. Unlike most other matrix materials, agarose is rela- 
tively translucent. This helps the spectrofluorimeter “see 
through” the matrix and detect the bound fluorescence. 
Commercial preparations of Agarose for packing affinity 
columns consist of beaded 4% to 6% agarose. These prod- 
50 ucts are available derivatized with a variety of active groups 
or ligands that are useful for BDC trap material: Protein-A, 
Protein-G, Anti-antibodies, Ion Exchange groups, etc. 
However, 4% agarose is not presently available in a form 
transparent enough for use in the trap cell. The lowest 
55 concentration of commercially available agarose beads is 
1% and is sold underivatized for use in size exclusion 
chromatography. One percent agarose beads were obtained 
commercially and derivatized with ligand using techniques 
known in the art. 
Normally, IgG (including goat IgG) is a cation (positively 
charged) at a pH near 7 .  However, IgG that has been highly 
derivatized with fluorescein isothiocyanate (FITC) may 
become anionic (negatively charged) at neutral pH. This is 
due to the decreased number of positively charged lysine 
65 residues and the added acidic character of the fluorescein 
molecule. This turned out to be the case with the FITC-label 
used in this example; therefore an anion exchange material 
60 
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was chosen for the trap material. N,N-diethyenediamine was 
coupled to 1% agarose beads with the CDI reaction 
(described in detail below): giving the agarose DEAE 
(diethylaminoethyl) anion exchange functionality. 
derivatized in our laboratory. The derivatized agarose col- 
umn trap layer acts like a 3 dimensional filter to trap 
fluorescent label detached from the displacement layer. 
The agarose beads were derivatized according to the 
5 method of Bethel1 (G. S. Bethell; et al: Journal of 
Chromatography, 219 (1981) p361-371). Briefly, the agar- 
ose beads were activated with carbonyldiimidizole (CDI) in 
dioxane (anhydrous) solvent and then transferred to an 
aqueous carbonate buffer (1 molar pH 8,5-10) and incubated 
Displacement Layer 90a Fabrication 
The displacement layer is currently made from cellulose 
paper (Whatman 3MM) is 
derivatized by conjugation with biotin via a synthetic reac- 
paper base’ The 
tion at the Research Laboratory (NRL) by with the trap reagent. Imidazolyl carbamate was chosen 
Dr. David because it reacts with available amino groups on the trap- the general approach Of which is 
described here. A spacer arm is attached to the glucosidic ping reagents to form stable N-dkyl  
hydroxyl groups of the cellulose fiber matrix of the Paper. conditions as opposed to other possible matrix materials 
This, in turn, was further modified by ConjWation with such as Epoxy activated materials, which require relatively 
biotin. It will be recognized by persons of ordinary skill in harsh reaction conditions. Since the signal detected from the 
the art that other chemistries well known in the art could be trap layer is based upon reporter dye molecule attached to 
substituted here for the above biotin conjugation of the filter the antibody, treatments limiting the non-specific binding of 
paper and would provide essentially the same result for the protein to the active matrix are not necessary. The trap 
purposes of the present example of the present invention, reagents attach to the gel via their amino groups (lysine 
namely biotin derivatized paper. After the derivatization residues of Proteins). The trapping reagent coupled to the 
steps the paper is cut into small disks (4 mm in diameter) and 2o agarose beads was 2-(diethYlamino)-ethYlamine. This Pro- 
stored in a dry state, The disks were rehydrated with water vides the anion exchange functionality of diethylaminoethyl 
and then washed with Mops Buffered Saline (MBS: 0.01M (DEAE). 
M~~~ (4-morp~o~inepropanesu~fonic acid), 0 . 1 5 ~  NaC1, p~ For initial trap testing, the derivatized agarose beads were 
body. 2s volume in 1 cc syringe barrels) and equilibrated with 0.01M 
MOPS buffer pH 6.8 (MOPS). Following this step, 2 pg 
Polyclonal antibodies were chosen for this test system. GAB-FITC in 4oo pl MOPS was added to the column, and 
However, it is anticipated, that in its preferred form of the the column was washed with ,1,5 ml MOPS, The column 
present invention the layer will be comprised of monoclonal was then observed under uv illumination, Good tapping 
antibodies of specific dissociation constants tailored to the 3o ability was indicated by a bright fluorescent band trapped 
operational life time and flow rates of the eventual field near the top of the gel bed, 
version of the device. To complete preparation of the dis- DEAE agarose was characterized for “quality of binding,, 
of GAB FITC. The DEAE gel matrix was evaluated by placement layer, fluorescein isothiocyanate labeled Goat 
anti-biotin (GAB-FITC) is incubated at 4” C. for a period of increasing the salt content of the buffer, O,OIM MOPS pH 
under 
6.8) prior to reaction with dye conjugated antibiotin anti- packed into a glass flow (o.2 m1 packed 
24 hr at a concentration Of o’2 mg/ml with the biotin-paper 35 6.8, from 
in to 2 molar NaC1, Results showed that there was no sharply defined salt concentration that would dis- buffered (MBS) in the presence Of 0’25% 
bovine serum (BSA)’ The GAB-F1TC attaches 
specifically to the solid phase biotin; the BSA minimizes 
nonspecific protein binding. The disk is then washed repeat- 
place the FITC-GAB. Instead, the antibody was displaced 
starting at a NaCl concentration of 0,05M and was not 
completely removed until 2M, It was determined that edly with fresh MBS, and both disk and 
for fluorescence with a uv lamp’ The inspected 4o salt gives the best binding with 0.05 molar a close second, However, 1.5M NaCl displaced most ofthe florescence from 
the column. The lack of a sharply-defined elution band layer is stored in the dark at 4” C. 
adapter and placed into the flow path Of a Sources of heterogeneity include: the antibodies’ polyclonal 
HPLC apparatus. The apparatus consists Of a buffer 45 nature, denaturation of the protein during purification/ 
5).  To minimize background signal the detector is located is reported to be an average FIP molar ratio of 3.7, While 
perpendicular to the excitation beam. The spectrofluorimeter useful for determining optimum conditions for the 
operated at an excitation frequency of 490 nm and emission BDC flow tests, this ionic heterogeneity does not indicate 
frequency of 520 nm. 50 any lack of performance of this reagent in the BDC. 
Before actual testing with sample injections, the displace- The DEAE gel matrix column was adapted to the spec- 
ment disk was washed free of loosely-bound antibody by trofluorimeter in its’ own flow cell and flow tested with 
pumping buffer though the system until the fluorescence injections of GAB-FITC using MOPS buffer. With a rela- 
base line slope was essentially horizontal. Initial leaching of tively high flow rate of 0.5 ml/min and high hydrostatic 
label was not surprising since the antibody employed is 55 pressure, the repeatability of the results were variable 
PolYclonal and comprised of several distinct molecular depending on the degree of compression of the gel. Changes 
species with differing affinities for the biotin on the conju- in flow rates in clearly visible changes in length of 
gated Paper. After sufficient washing, the labeled disks were the trap layer material column. Since the gel is translucent 
ready to be tested for biotin detection sensitivity. and not transparent, compression causes a problem by 
Trap 92a Fabrication 60 changing the degree to which light scatters. This light cannot 
A “column ” trap cell was fabricated for this pumped be completely distinguished from a true fluorescent signal 
flow-through mode example. As previously discussed there due to the excellent but not perfect optical “filter” systems 
are many matrixes available as the solid phase in the trap in the spectrofluorimeter. For the purposes of evaluating the 
column. Agarose was chosen as the packing material in the material this problem was overcome by using an HPLC 
current example trap cell. Because of their relative 65 pump to precisely control the flow at a constant rate of 0.25 
translucence, 1% agarose beads (100-200 mesh) were pur- ml per minute. This caused minimal compression of the gel 
chased from Bio-Rad Laboratories (Bio-Gel A150m) and and therefore acceptable signal stability. 
For flow testing, the disks were fitted into a Luer-lock indicates the GAB-FITC is heterogenous in ionic character, 
reservoir, pump, injector, and spectrofluorimeter (See storage, and variable molar ratios of FITC to antibody which 
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Compression artifacts are not anticipated to occur with the 
more ridged polymers available for use for the trapping 
matrix nor in the saturationitranspiration mode manifesta- 
tions of the device because of the very low flow rates 
involved. For use as a “Drug Badge”, the flow rate is on the 
order of 0.25 ml per day. 
The testing of the trap layer material under these condi- 
tions demonstrated that it is capable of efficiently trapping 
the signal molecule. Aliquots of 0.1 pg of GAB-FITC 
delivered in a volume of 50 pl at a concentration of 2 pgiml 
were injected into the flow stream and recovered with high 
efficiency as detectable fluorescence. Furthermore, multiple 
injections of five aliquots showed no evidence of trap layer 
saturation by the reporter molecule. Qualitative hand inspec- 
tion of the column under ultraviolet light showed the visible 
band to be less than one millimeter in depth. 
Pumped Flow-Through Mode BDC: flow testing. 
The following text refers to FIG. 5 .  
Adisplacement layer cell 90 was mounted upstream of the 
trap column cell 92, and connected to it by flexible Tygon 
tubing 91, in a high pressure liquid chromatography (HPLC) 
system (however, run at low pressure). The displacement 
cell 90 consists of a displacement layer 90a of GAB-FITC 
antigenically bound to a biotin solid phase (described 
previously), and a glass wool layer 87a to support it. The 
trap cell 92 consists of a glass wool layer 87b supporting the 
trap matrix (previously described) of DEAE-agarose 92a. 
The HPLC system is a Perkin-Elmer model 650-15 Fluo- 
rescence Spectrophotometer 94, with buffer reservoir 96, 
stainless steel tubing 91a, digitally controlled pump 93a, 50 
pl sample injector 95, and recorder 97. The HPLC detector 
consists of a deuterium lamp light source 84a and a photo- 
multiplier tube detector 84b. The BDC was operated in 
Mops Buffered Saline solution at a flow rate of 0.25 mlimin. 
50 pl samples were injected into the flow stream. FIG. 6 
shows results from injection of two 100 pgiml samples over 
a 10 minute time period. As expected, the trap layer showed 
an increasing baseline with multiple injections of sample 
over time. The increasing baseline is indicative of the 
integrationiamplification function of the trap layer. Data 
presented in FIG. 6 has been adjusted by a baseline sub- 
traction algorithm to counter the effects of photobleaching of 
the fluorescein dye molecule. A more stable dye molecule 
such as Texas Red is to be preferred for the present inven- 
tion. The device was able to detect the model compound 
across the middle of the concentration range found in 
clinical tests of perspiration for cocaine (0.034-317 pgiml). 
It will be appreciated by persons of skill in the art that 
other designs and processes to implement the present inven- 
tion can be used without departing from the spirit and scope 
of the present invention. 
What is claimed is: 
1. An apparatus for detecting an analyte in the perspiration 
a first layer, having a surface which facilitates attachment 
of the apparatus to the skin of the subject, having 
immobilized thereon the analyte to be detected; 
said first layer further having labeled antibodies directed 
to said analyte, said labeled antibodies being of a type 
capable of linking to said immobilized analyte through 
an antigen-antibody linkage; 
a second trap layer, adjacent the first layer, comprising an 
antibody immobilizing material therein, said antibody 
immobilizing material being directed against said 
labeled antibodies; 
an optically and biochemically isolating spacer between 
said first layer and said second trap layer and formed of 
a material permitting said labeled antibodies to travel 
through it; 
of a subject, said apparatus comprising: 
14 
means for detecting the label on said labeled antibody, 
said detecting means positioned to detect when said 
labeled antibody is bound to said antibody immobiliz- 
ing material of said second layer; and 
means, coupled to said means for detecting, for signaling 
a receiver when said means for detecting detects the 
labeled antibody bound to the antibody immobilizing 
material. 
2. The apparatus of claim 1 further comprising a semi- 
permeable membrane disposed below the first layer of said 
apparatus and adjacent the skin of the subject. 
3. The apparatus of claim 1 wherein the analyte is 
covalently bound to said first layer. 
4. The apparatus of claim 1 wherein said antibody immo- 
bilizing material is selected from the group consisting of 
anti-antibody, protein-A, protein-(;, lectin, and ion exchange 
groups. 
5 .  The apparatus of claim 1 wherein the labeled antibodies 
are labeled with a fluorescent, phosphorescent, enzyme, 
dyed-microsphere and other antibody label. 
6. The apparatus of claim 1 wherein said means for 
detecting the label on said labeled antibody comprises a light 
emitting diode directed at said antibody immobilizing mate- 
rial for exciting the label on said labeled antibody, a filter or 
filters for reducing light emitted from said labeled antibody 
25 which is not within a predetermined wavelength range, and 
a photodetector for detecting the light emitted by the label. 
7. The apparatus of claim 1 wherein the analyte to be 
detected comprises a drug of abuse. 
8. The apparatus of claim 1 further comprising a means 
30 for holding said entire apparatus against the skin of the 
9. The apparatus of claim 1 wherein said optically iso- 
10. The apparatus of claim 1 wherein said optically 
11. An apparatus for detecting an analyte in the perspi- 
a first layer, having a surface which facilitates attachment 
of the apparatus to the skin of the subject, having 
immobilized thereon an anti-analyte antibody; 
said first layer further having a labeled analyte to be 
detected bound by said immobilized anti-analyte anti- 
body through an antigen-antibody linkage; 
a second trap layer, adjacent the first layer, comprising an 
analyte immobilizing material therein, said analyte 
immobilizing material being directed against said 
labeled analyte; 
an optically and biochemically isolating spacer between 
said first layer and said second trap layer and formed of 
a material permitting said labeled analyte to travel 
through it; 
means for detecting the label on said labeled analyte, said 
detecting means positioned to detect when said labeled 
analyte is bound to said analyte immobilizing material 
of said second layer; and 
means, coupled to said means for detecting, for signaling 
a receiver when said means for detecting detects the 
labeled analyte bound to the analyte immobilizing 
12. The apparatus of claim 11 further comprising a 
semipermeable membrane disposed below the first layer of 
said apparatus adjacent the skin of the subject. 
13. The apparatus of claim 11 wherein the anti-analyte 
65 antibody is covalently bound to said first layer. 
14. The apparatus of claim 11 wherein said labeled 
analyte immobilizing material is selected from the group 
5 
2o 
subject. 
lating spacer is incorporated into the first layer. 
35 isolating spacer is incorporated into the second layer. 
ration of a subject, said apparatus comprising: 
40 
45 
so 
5s 
60 material. 
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consisting of anti-analyte antibodies, anti-label antibodies, 
protein-A, protein-(;, lectin, and ion exchange groups. 
15. The apparatus of claim 11 wherein the labeled analYte 
17. The apparatus of claim 11 wherein the analyte to be 
18. The apparatus of claim 11 further comprising a means 
detected comprises a drug of abuse. 
is labeled with a fluorescent, phosphorescent, enzyme, dye for holding said entire apparatus against the skin of the ' subject. or dyed-microsphere label. 16. The apparatus of claim 11 wherein said means for 
detecting the label on said labeled analyte comprises a light 
material for exciting the label on said labeled analyte, a filter 
or filters for reducing light emitted from the label which is i o  isolating spacer is incorporated into the second layer. 
not within a predetermined wavelength range, and a photo- 
19. The apparatus Of l1 wherein said optically 
20. The apparatus of claim 11 wherein said optically 
emitting diode directed at said labeled analyte immobilizing spacer is incorporated into the first layer. 
detector for detecting the light emitted by the label. * * * * *  
